# A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents

> **NCT04661397** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 37 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
- **DRUG:** Darunavir
- **DRUG:** Emtricitabine/Tenofovir Alafenamide
- **DRUG:** Cobicistat

## Key facts

- **NCT ID:** NCT04661397
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-05
- **Primary completion:** 2021-07-02
- **Final completion:** 2021-07-02
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04661397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04661397, "A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04661397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*